Federal Register / Vol. 65, No. 186 / Monday, September 25, 2000 / Notices 57621

FOR FURTHER INFORMATION CONTACT: The

Offices of the Mojave National Preserve,

Barstow, California 92311. Tel. (760)

255–8801.

SUPPLEMENTARY INFORMATION: In order to

resolve the encroachment of a private

residence and ranch headquarters on

federal land, it is necessary for the

National Park Service to effect a land

exchange at Mojave National Preserve,

San Bernardino California. Comments

received in response to the Federal

Register Notice of Realty Action,

included requests for a public hearing

on the exchange. National Park Service

staff will brief those in attendance at the

hearing on the history, purpose, and

procedures involved in the exchange.

For more detailed information on the

proposed exchange, see Federal

Register Notice of Realty Action

published April 18, 2000 (Volume 65,

Number 75, pages 20831–20832).

Dated: September 12, 2000.

Cynthia L. Ip,

Acting Regional Director, Pacific West Region.

[FR Doc. 00–24503 Filed 9–22–00; 8:45 am]

BILLING CODE 4310–70–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances;

Notice of Application

Pursuant to Section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(I)), the

Attorney General shall, prior to issuing

a registration under this Section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under Section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with Section

1301.34 of Title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on June 19, 2000, Abbott

Laboratories, 1776 North Centennial

Drive, McPherson, Kansas 67460–1247,

made application to the Drug

Enforcement Administration to be

registered as an importer of remifentanil

(9739), a basic class of controlled

substance listed in Schedule II.

The firm plans to import the

remifentanil to manufacture Ultiva for

the U.S. market.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of this basic class of

controlled substance may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.43 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections or

requests for a hearing may be addressed,

in quintuplicate, to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, D.C.

20537, Attention: DEA Federal Register

Representative (CCR), and must be filed

no later than October 25, 2000.

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1301.34(b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import a basic class of

any controlled substance in Schedule I

or II are and will continue to be required

to demonstrate to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1301.34(a), (b), (c), (d), (e), and (f)

are satisifed.

Dated: September 8, 2000.

John H. King,

Office of Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–24556 Filed 9–22–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to Section 1301.33(a) of Title

21 of the Code of Federal Regulations

(CFR), this is notice that on July 24,

2000, American Radiolabeled Chemical,

Inc., 11624 Bowling Green Drive, St.

Louis, Missouri 63146, made

application by renewal to the Drug

Enforcement Administration (DEA) for

registratin as a bulk manufacturer of the

basic classes of controlled substances

listed below:

Drug Schedule

Gamma hydroxybutyric acid

(2010).

I

Lysergic acid diethylamide (7315) I

Dimethyltryptamine (7435) ........... I

Dihydromorphine (9145) ............... I

Phencyclidine (7471) .................... II

Cocaine (9041) ............................. II

Codeine (9050) ............................. II

Drug Schedule

Hydromorphone (9150) ................ II

Benzoylecgonine (9180) ............... II

Meperidine (9230) ........................ II

Metazocine (9240) ........................ II

Morphine (9300) ........................... II

Oxymorphone (9652) ................... II

The firm plans to bulk manufacture

small quantities of the listed controlled

substances as radiolabeled compound.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substance

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, DC 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than

November 24, 2000.

Dated: September 6, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control Drug Enforcement

Administration.

[FR Doc. 00–24560 Filed 9–22–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances;

Notice of Application

Pursuant to Section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this Section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under Section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with Section

1301.34 of Title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on July 5, 2000, Glaxo

Wellcome Inc., Attn: Jeffrey A. Weiss,

1011 North Arendell Avenue, P.O. Box

1217, Zebulon, North Carolina 27597–

2309, made application by renewal to

the Drug Enforcement Administration to

be registered as an importer of

remifentanil (9739), a basic class of

controlled substance listed in Schedule

II.